Emerging drugs for postmenopausal osteoporosis

Bibliography

• Klibanski A, Adams-Campbell L, Bassford T, et al. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6):785-95
   PubMed Web of Science ®Google Scholar
• WHO Study Group on assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: World Health Organization; 1994
   Google Scholar
• Baim S, Binkley N, Bilezikian JP, et al. Official positions of the International society for clinical densitometry and executive summary of the 2007 ISCD position development conference. J Clin Densitom 2008;11(1):75-91
   PubMed Web of Science ®Google Scholar
• Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level: technical report (2007). World Health Organization Collaborating Centre for metabolic bone diseases. Sheffield, UK: University of Sheffield
   Google Scholar
• National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass in our nation. Washington, DC: National Osteoporosis Foundation; 2002
   Google Scholar
• US Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: US Department of health and human services, Office of the Surgeon General; 2004
   Google Scholar
• Dennison E, Cooper C. Epidemiology of osteoporotic fractures. Horm Res 2000;54(Suppl):58-63
   PubMed Web of Science ®Google Scholar
• Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995;332(12):767-73
   PubMed Web of Science ®Google Scholar
• Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the national osteoporosis risk assessment. JAMA 2001;286(22):2815-22
   PubMed Web of Science ®Google Scholar
• Riggs BL, Melton LJ III. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17(Suppl):505S-11S
   PubMed Web of Science ®Google Scholar
• Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001-5
   PubMed Web of Science ®Google Scholar
• Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22(3):465-75
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005;16(3):229-38
   PubMed Web of Science ®Google Scholar
• Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 2005;27(1):1-11
   PubMed Web of Science ®Google Scholar
• Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007;357(9):905-16
   PubMed Web of Science ®Google Scholar
• McClung MR, San MJ, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165(15):1762-8
   PubMed Web of Science ®Google Scholar
• Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19(7):1059-66
   PubMed Web of Science ®Google Scholar
• Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004;95(11):1046-57
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89(2):309-19
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292(4):490-5
   PubMed Web of Science ®Google Scholar
• Atley LM, Mort JS, Lalumiere M, et al. Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by cross-linked N-telopeptide neoepitope. Bone 2000;26(3):241-7
   PubMed Web of Science ®Google Scholar
• Zaidi M, Troen B, Moonga BS, et al. Cathepsin K, osteoclastic resorption, and osteoporosis therapy. J Bone Miner Res 2001;16(10):1747-9
   PubMed Web of Science ®Google Scholar
• Gazzerro E, Canalis E. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 2006;7(1-2):51-65
   PubMed Web of Science ®Google Scholar
• Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008;29(5):535-59
   PubMed Web of Science ®Google Scholar
• Baron R, Rawadi G. Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep 2007;5(2):73-80
   PubMedGoogle Scholar
• Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet 2003;63(3):192-7
   PubMed Web of Science ®Google Scholar
• Wergedal JE, Veskovic K, Hellan M, et al. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab 2003;88(12):5778-83
   PubMed Web of Science ®Google Scholar
• Kaiser M, Mieth M, Liebisch P, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008;80(6):490-4
   PubMed Web of Science ®Google Scholar
• Cooper C, Johnell O, Lips P, et al. The global burden of vertebral fractures [abstract]. J Bone Miner Res 2002;17(Suppl 1):S202
   Web of Science ®Google Scholar
• Lewiecki EM. Update on bone density testing. Curr Osteoporos Rep 2005;3(4):136-42
   PubMedGoogle Scholar
• World health organization: FRAX WHO Fracture Risk Assessment Tool. 2008. Available from: http://www.shef.ac.uk/FRAX/ [Last accessed 22 October 2008]
   Google Scholar
• National osteoporosis foundation: Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC, National Osteoporosis Foundation; 2008
   Google Scholar
• Maclean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148(3):197-213
   PubMed Web of Science ®Google Scholar
• Lewiecki EM. Review of guidelines for bone mineral density testing and treatment of osteoporosis. Curr Osteoporos Rep 2005;3(3):75-83
   PubMedGoogle Scholar
• Curtis JR, Carbone L, Cheng H, et al. Longitudinal trends in use of bone mass measurement among older americans, 1999-2005. J Bone Miner Res 2008;23(7):1061-7
   PubMed Web of Science ®Google Scholar
• US preventive services task force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 2002;137(6):526-8
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int 2005;16(2):134-41
   PubMed Web of Science ®Google Scholar
• Delmas PD, Van De Langerijt L, Watts NB, et al. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res 2005;20(4):557-63
   PubMed Web of Science ®Google Scholar
• Foley KA, Foster SA, Meadows ES, et al. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. Med Care 2007;45(9):902-6
   PubMed Web of Science ®Google Scholar
• Panneman MJ, Lips P, Sen SS, et al. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int 2004;15(2):120-4
   PubMed Web of Science ®Google Scholar
• Kiebzak GM, Beinart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002;162(19):2217-22
   PubMed Web of Science ®Google Scholar
• Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18(8):1023-31
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81(8):1013-22
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Baim S, Siris ES. Osteoporosis care at risk in the United States. Osteoporos Int 2008
   Google Scholar
• The lewin group: Assessing the costs of performing DXA services in the office-based setting (survey data report prepared for American Association of Clinical Endocrinologists. International Society for Clinical Densitometry, The Endocrine Society, and American College of Rheumatology). 2007. http://www.aace.com/advocacy/leg/pdfs/DXAExecutiveSummary.pdf (Accessed Feb 18, 2009).
   Google Scholar
• Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 2005;20(2):177-84
   PubMed Web of Science ®Google Scholar
• Writing group for the women's health initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291(14):1701-12
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290(13):1729-38
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kleerekoper M, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287(20):2668-76
   PubMed Web of Science ®Google Scholar
• Prestwood KM, Kenny AM, Kleppinger A, et al. Ultralow-dose micronized 17β-estradiol and bone density and bone metabolism in older women - A randomized controlled trial. JAMA 2003;290(8):1042-8
   PubMed Web of Science ®Google Scholar
• Cranney A, Wells G, Willan A, et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23(4):508-16
   PubMed Web of Science ®Google Scholar
• Cranney A, Tugwell P, Adachi J, et al. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23(4):517-23
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005;21(3):391-401
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809-22
   PubMed Web of Science ®Google Scholar
• Gertz BJ, Holland SH, Kline WF, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995;58:288-98
   PubMed Web of Science ®Google Scholar
• Recker RR, Gallagher R, Maccosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80(7):856-61
   PubMed Web of Science ®Google Scholar
• Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60(8):896-905
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Bone HG, Crepaldi G, et al. Alendronate 70 mg once weekly is therapeutically equivalent to alendronate 10 mg daily for treatment of postmenopausal osteoporosis. Aging Clin Exp Res 2000;12:1-12
   Web of Science ®Google Scholar
• Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103-11
   PubMed Web of Science ®Google Scholar
• Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20(8):1315-22
   PubMed Web of Science ®Google Scholar
• Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54(6):1838-46
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene - Results from a 3-year randomized clinical trial. JAMA 1999;282(7):637-45
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295(23):2727-41
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355(2):125-37
   PubMed Web of Science ®Google Scholar
• Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109(4):267-76
   PubMed Web of Science ®Google Scholar
• Knopp JA, Diner BM, Blitz M, et al. Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 2005;16(10):1281-90
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146(5):326-39
   PubMed Web of Science ®Google Scholar
• Marie PJ, Hott M, Modrowski D, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993;8(5):607-15
   PubMed Web of Science ®Google Scholar
• Marie PJ, Ammann P, Boivin G, et al. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001;69(3):121-9
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350(5):459-68
   PubMed Web of Science ®Google Scholar
• Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90(5):2816-22
   PubMed Web of Science ®Google Scholar
• Blake GM, Lewiecki EM, Kendler DL, et al. A review of strontium ranelate and its effect on DXA scans. J Clin Densitom 2007;10(2):113-9
   PubMed Web of Science ®Google Scholar
• Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992;2(6):285-9
   PubMed Web of Science ®Google Scholar
• Commercial Insight: Osteoporosis DMHC2308. (27 June 2007) New York City, New York, USA, Datamonitor.
   Google Scholar
• Lewiecki EM. RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 2006;6(10):1041-50
   PubMed Web of Science ®Google Scholar
• Poole KE, Van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005;19(13):1842-4
   PubMed Web of Science ®Google Scholar
• Krause C, De Gorter DJJ, Karperien M, et al. Editor: Rosen CJ. Chapter 2. Signal transduction cascades controlling osteoblast differentiation. Primer on the metabolic bone diseases and disorders of mineral metabolism 2008;7(1):10-6
   Google Scholar
• Heider U, Kaiser M, Mieth M, et al. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 2009;82(1):31-8
   PubMed Web of Science ®Google Scholar
• Glantschnig H, Hampton R, Wei N, et al. Fully human anti-DKK1 antibodies increase bone formation and resolve osteopenia in mouse models of estrogen-deficiency induced bone loss. J Bone Miner Res 2008;23(Suppl 1):S60
   Google Scholar
• Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann NY Acad Sci 2001;949:317-26
   PubMed Web of Science ®Google Scholar
• Khosla S, Melton LJ III. Fracture risk in primary hyperparathyroidism. J Bone Miner Res 2002;17:N103-7
   PubMed Web of Science ®Google Scholar
• Hodsman A, Bone H, Gallagher C, et al. Ostabolin-CTM increases lumbar spine and hip BMD after 1 year of therapy: results of a phase II clinical trail. J Bone Miner Res 2007;22(Suppl 1):S38
   Google Scholar
• Horwitz MJ, Tedesco MB, Gundberg C, et al. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88(2):569-75
   PubMed Web of Science ®Google Scholar
• O'Dea L, Lyttle CR, Rosen CJ. BA058, a novel analog of of human parathyroid hormone-related peptide (PTHrP), induces evidence of bone formation without evidence of bone resprption over 7 days of exposure [abstract P2-P137]. 89th Annual Meeting of The Endocrine Society 2007, Toronto, Canada. 2 - 5 June, 2007.
   Google Scholar
• Kostenuik PJ, Ferrari S, Pierroz D, et al. Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone. J Bone Miner Res 2007;22(10):1534-47
   PubMed Web of Science ®Google Scholar
• Ruckle J, Jacobs M, Kramer W, et al. A Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women. J Bone Miner Res 2008 [Epub ahead of print]
   Google Scholar
• Zhao H, Kitaura H, Sands MS, et al. Critical role of beta3 integrin in experimental postmenopausal osteoporosis. J Bone Miner Res 2005;20(12):2116-23
   PubMed Web of Science ®Google Scholar
• Anderson HC. An antagonist of osteoclast integrins prevents experimental osteoporosis. J Clin Invest 1997;99(9):2059
   PubMed Web of Science ®Google Scholar
• Murphy MG, Cerchio K, Stoch SA, et al. Editor: Rosen CJ. Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2005;90(4):2022-8
   PubMed Web of Science ®Google Scholar
• Ross FP. Chapter 3. Osteoclast biology and bone resorption. Primer on the metabolic bone diseases and disorders of mineral metabolism 2008;7(1):16-22
   Google Scholar
• Peroni A, Zini A, Braga V, et al. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol 2008;59(1):125-9
   PubMed Web of Science ®Google Scholar
• Jamal SA, Browner WS, Bauer DC, et al. Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res 1998;13(11):1755-9
   PubMed Web of Science ®Google Scholar
• Jamal SA, Cummings SR, Hawker GA. Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial. J Bone Miner Res 2004;19(9):1512-7
   PubMed Web of Science ®Google Scholar
• Rejnmark L, Vestergaard P, Mosekilde L. Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J Bone Miner Res 2006;21(11):1811-7
   PubMed Web of Science ®Google Scholar
• Wimalawansa SJ. Nitric oxide: novel therapy for osteoporosis. Expert Opin Pharmacother 2008;9(17):3025-44
   PubMed Web of Science ®Google Scholar
• Wimalawansa SJ, Grimes J, Wilson A, et al. Prevention of postmenopausal osteoporosis using nitroglycerine: NOVEL clinical study. J Bone Miner Res 2008;23(Suppl 1):S462
   Google Scholar
• Wilder L, Gamse R, Seuwen K, et al. A novel calcium-sensing receptor antagonist leads to dose-dependent transient release of parathyroid hormone after oral administration to healthy volunteers- and initial prood-of-concept for a potential new class of anabolic osteoporosis therapeutics. J Bone Miner Res 2008;23(Suppl 1):S49
   Web of Science ®Google Scholar
• Fitzpatrick LA, Brennen E, Kumar S, et al. Ronacaleret, a novel calcium-sensing receptore antagonist, demonstrtes potential as an oral bone-forming therapy in helathy postmenopausal women. J Bone Miner Res 2008;23(Suppl 1):S50
   Web of Science ®Google Scholar
• Compston JE, Watts NB. Combination therapy for postmenopausal osteoporosis. Clin Endocrinol 2002;56(5):565-9
   PubMed Web of Science ®Google Scholar
• Bilezikian JP. Editor: Rosen CJ. Chapter 53. Combination Anabolic and Antiresorptive Therapy for Osteoporosis. Primer on the metabolic bone diseases and disorders of mineral metabolism 2008;7(1):252-4
   Google Scholar
• Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5
   PubMed Web of Science ®Google Scholar
• Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998;102(8):1627-33
   PubMed Web of Science ®Google Scholar
• Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005;353(6):566-75
   PubMed Web of Science ®Google Scholar
• Ettinger B, San MJ, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19(5):745-51
   PubMed Web of Science ®Google Scholar
• Miller P, Lindsay R, Watts N, et al. Patients previously treated with risedronate demonstrate greater responsiveness to teriparatide than those previously treted with alendronate: the OPTAMISE study. J Bone Miner Res 2007;22(Suppl 1):S26
   Web of Science ®Google Scholar
• Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000;85(9):3069-76
   PubMed Web of Science ®Google Scholar
• Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349(13):1207-15
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349(13):1216-26
   PubMed Web of Science ®Google Scholar
• Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005;20(11):1905-11
   PubMed Web of Science ®Google Scholar
• Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004;164(18):2024-30
   PubMed Web of Science ®Google Scholar
• Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 2004;15(12):992-7
   PubMed Web of Science ®Google Scholar
• Lane NE, Sanchez S, Modin GW, et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000;15(5):944-51
   PubMed Web of Science ®Google Scholar
• Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005;20(9):1507-13
   PubMed Web of Science ®Google Scholar
• Lane NE, Cosman F, Bolognese M. Transdermal delivery of hPTH (1-34) (ZP-PTH) is effective in increasing bone mineral density of the lumbar spine and hip in postmenopausal women with osteoporosis. Arthritis Rheum 2008;9(Suppl 1). [Abstract] page 2.
   Google Scholar
• Shimizu M. [PTH]. Clin Calcium 2002;12(8):1148-51
   PubMedGoogle Scholar
• Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008;43(2):222-9
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res 2007;22:1832-41
   PubMed Web of Science ®Google Scholar
• McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354(8):821-31
   PubMed Web of Science ®Google Scholar
• Cummings SR, McClung MR, Christiansen C, et al. A phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: results from the FREEDOM trial. J Bone Miner Res 2008;23(Suppl):S80
   Google Scholar
• Amgen Inc. Form 8-K. 2008. Available from: http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-sec [Last accessed: 16 September 2008]
   Google Scholar
• Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24(1):153-161
   PubMed Web of Science ®Google Scholar
• Kendler DL, Benhamou CL, Brown JP, et al. Effects of denosumab vs alendronate on bone mineral density (BMD), bone turnover markers (BTM), and safety in women previously treated with alendronate. J Bone Miner Res 2008;23(Suppl):S473
   Web of Science ®Google Scholar
• McClung M, Bone H, Cosman F, et al. A randomized, double-blind, placebo-controlled study of odanacatib (MK-822) in the treatment of postmenopausal women with low bone mineral density: 24 month results. J Bone Miner Res 2008;23(Suppl 1):S82
   Web of Science ®Google Scholar
• Gruber C, Gruber D. Bazedoxifene (Wyeth). Curr Opin Investig Drugs 2004;5(10):1086-93
   PubMedGoogle Scholar
• Miller PD, Christiansen C, Hoeck HC, et al. Efficacy of bazedoxifene for prevention of postmenopausal osteoporosis: results of a 2-year, phase 3, placebo- and active-controlled study. J Bone Miner Res 2007;22(Suppl 1):S59
   Google Scholar
• Chesnut CH, Christiansen C, Hoeck HC, et al. Safety and tolerability of bazedoxifene for the prevention of postmenopausal osteoporosis. J Bone Miner Res 2007;22(Suppl 1):S460
   Google Scholar
• Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopoausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 2007;22(Suppl 1):S58
   Web of Science ®Google Scholar
• Adachi JD, Chesnut III CH, Brown JP, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 2007;22(Suppl 1):S460
   Google Scholar
• Van Duren D, Ronkin S, Pickar J, et al. Bazedoxifene combined with conjugated estrogens: a novel alternative to traditional hormone therapies. Fertil Steril 2006;86(Suppl 1):S88-9
   Web of Science ®Google Scholar
• Pickar J, Archer DF, Constantine G, et al. A double-blind, placebo-controlled, phase III study of bazedoxifene/conjugated estrogens in postmenopausal women: effects on endometrium. Program and abstracts of the 89th Annual Meeting of the Endocrine Society; June 2-5, 2007; Toronto, Ontario, Canada 2007
   Google Scholar
• Lindsay R, Ronkin S, Constantine G, et al. A double-blind, placebo-controlled, phase III study of bazedoxifene/conjugated estrogens in postmenopausal women: effects on BMD. Program and abstracts of the 89th Annual Meeting of the Endocrine Society; June 2-5, 2007; Toronto, Ontario, Canada 2007
   Google Scholar
• Cummings SR, Eastell R, Ensrud K, et al. The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial. J Bone Miner Res 2008;23(Suppl 1):S81
   Web of Science ®Google Scholar
• Bolognese M, Krege J, Utian WH, et al. Arzoxifene in postmenopausal women with normal or low bone mass. J Bone Miner Res 2008;23(Suppl 1):S211
   Google Scholar
• Brixen K, Krogsgaard K, Christgau S, et al. Effect of three doses of strontium malonate (NB S101) on markers of bone turnover and bone mineral density: the STRONG study [abstract]. Calcif Tissue Int 2008;82(Suppl 1):Su-P413
   Google Scholar
• Kanis JA, Oden A, Johnell O, et al. Uncertain future of trials in osteoporosis. Osteoporos Int 2002;13(6):443-9
   PubMed Web of Science ®Google Scholar
• Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009;20(2):291-297
   PubMed Web of Science ®Google Scholar